Tri-Heart

Verify with FDA CVM →

21 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
21
Total Reports
2
Deaths Reported
950.0%
Death Rate

Active Ingredients

Tri-Heart

Administration Routes

OralUnknown

Species Affected

Dog 21

Most Affected Breeds

Retriever - Labrador 4
Terrier (unspecified) 2
Terrier - Bull - American Pit 2
Dog (unknown) 2
Chihuahua 1
Retriever - Golden 1
Spaniel - Boykin 1
Black Mouth Cur 1
Poodle (unspecified) 1
Sheepdog - Shetland 1

Most Reported Reactions

Lack of efficacy (endoparasite) - heartworm 14
Abnormal cytology 2
Vomiting 2
Seizure NOS 2
INEFFECTIVE, HEARTWORM ADULTS 1
Limping 1
Licking 1
Swollen feet 1
Papilloma 1
Emesis (multiple) 1
Death 1
Not eating 1

Outcome Breakdown

Ongoing
16 (76.2%)
Recovered/Normal
2 (9.5%)
Outcome Unknown
1 (4.8%)
Died
1 (4.8%)
Euthanized
1 (4.8%)

Data Summary

Metric Value
Total adverse event reports 21
Reports involving death 2
Case-fatality rate (reported events) 950.0%
Distinct species in reports 1
Distinct breeds in reports 15
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Tri-Heart Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 21 adverse event reports referencing Tri-Heart, including 2 reports in which the animal died — a 950.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Tri-Heart. Reported administration routes include Oral, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Tri-Heart reports are Dog (21 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (4), Terrier (unspecified) (2), Terrier - Bull - American Pit (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Tri-Heart are Lack of efficacy (endoparasite) - heartworm (14), Abnormal cytology (2), Vomiting (2), Seizure NOS (2). Of the 21 reports with a coded outcome, Ongoing is the leading category at 76.2%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Tri-Heart.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial